Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... underlining the therapeutic potential of targeting cancer stem cells to treat solid tumors. ... are made up of different types of cells and targeting cancer stem cells has a profound effect on tumor ... that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be ...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

... and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be ... MSM is the leader in the discovery of antibodies targeting multispanning membrane proteins. The company ... weight drugs currently on the market are targeting this kind of receptors. Debiopharm S.A. ...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins. The ... that these antibodies provide a novel approach to targeting tumor-associated proteins. Antibody targeting of tumor-associated proteins has demonstrated ...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... (23,6m EUR). - In Q2 the SPC3649 compound targeting hepatitis C finalized a single dose ... for preclinical trials. - Lead candidates targeting PCSK9, which is known to play a critical ... report the results of its phase I clinical trials targeting solid tumors with EZN2968 in the 2nd half of ....

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

... mechanistic attributes result in it selectively targeting tissues over-expressing EGFR while avoiding ... drugs result from their indiscriminant targeting of normal healthy tissues in addition to their ... monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.

... target cancer cells in one of two ways: (1) by targeting tumor-associated blood vessels; or (2) by targeting tumors directly. The Company's lead prodrug ... also be used to attack cancer cells directly by targeting the prodrug to enzymes believed to be found ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... inhibits tumor growth. Abstract 4794: targeting breast cancer stem cells through inhibition of ... Stem Cell Approaches for Identification and targeting Abstract Summary: According to ... role in mammary stem cell self-renewal and that targeting of cancer stem cells through inhibition of this ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... proteins (peptibodies) specifically targeting Ang1 (mL4-3) or Ang2 (L1-7(N)) alone or in ... April 20, 2009, 1:00 pm - 5:00 pm) -- Dual targeting of the receptor tyrosine kinase EGFRvIII and ... a fully human neutralizing antibody targeting the HGF:c-Met axis (AMG 102), with a fully human ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... first pre-clinical data on new BiTE antibodies targeting EGFR, HER-2, MCSP and CD33. In addition, data was ... trial of MT293, a humanized monoclonal antibody targeting denatured collagen, that is being developed for ... solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are ...

Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice

... between PF4 and RANTES is a novel approach to targeting inflammation that may lead to a new class of ... in inflammatory signaling." In addition to targeting PF4-RANTES heterodimers, Carolus Therapeutics has a second drug discovery program targeting the pro-inflammatory cytokine MIF (Macrophage ...

Isis Reports Financial Results and Highlights for Third Quarter of 2008

... 1 study on ISIS 333611, Isis' first CNS drug targeting SOD1 for the treatment of ALS -- Potential ... franchise with the addition of a new drug targeting PCSK9 and the initiation of clinical trials on ... the therapeutic use of antisense compounds targeting apolipoprotein B, U.S. Patent No. 7,407,943 ...

OncoMed Pharmaceuticals Completes Series B Financing

... is to improve cancer treatment by specifically targeting the key biologic pathways critical for the ... of cancer stem cells. OncoMed's antibodies targeting cancer stem cell proteins have the potential to ... that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be ...

Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award

... /PRNewswire/ -- The 2008 European Gene Expression targeting Platform Technology Innovation Award is presented ... occurs." The innovative gene expression targeting platform technology essentially facilitates ... a broad array of small molecule drugs targeting anti-inflammatory disorders as well as diseases ...

Halozyme Therapeutics Reports 2008 Second Quarter Financial Results

... company developing and commercializing products targeting the extracellular matrix, today reported ... provide an effective dermatologic treatment by targeting and degrading the fibrous components of the ... company developing and commercializing products targeting the extracellular matrix for the drug ...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

... Phase 1 clinical study on ISIS 353512, Isis' drug targeting CRP for the treatment of cardiovascular, ... -- Complete Phase 1 study with ISIS 325568, targeting GCGR for the treatment of type 2 diabetes ... 1 study on ISIS 333611, Isis' first CNS drug targeting SOD1 for the treatment of ALS -- Advance a ...

Halozyme Therapeutics Reports 2008 First Quarter Financial Results

... company developing and commercializing products targeting the extracellular matrix, today reported ... company developing and commercializing products targeting the extracellular matrix for the drug delivery, ... of different enzymes in its portfolio that are targeting significant areas of unmet need. Safe Harbor ...

Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9

... company developing and commercializing products targeting the extracellular matrix, today announced that it ... company developing and commercializing products targeting the extracellular matrix for the drug delivery, ... of different enzymes in its portfolio that are targeting significant areas of unmet need. Halozyme ...

JCI table of contents: April 22, 2008

... Nef is likely to impair blood cell development by targeting a PPAR-gamma/STAT5 signaling pathway. The authors ... D protein. This has led to the suggestion that targeting individual cyclin D proteins might provide a good ... Nox4 levels. The authors therefore suggested that targeting the adiponectin-AMPK-Nox4 pathway might protect ...

ARIUS presents new findings for anti-cancer antibody programs at AACR

... new data and program updates on cancer stem cell targeting antibodies- ... new findings from our cancer stem cell programs targeting CD44 and CD9 are of particular interest to ... as blood cancers. Our cancer stem cell antibody targeting CD9 differentially recognizes AML cancer stem ...

Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results

... company developing and commercializing products targeting the extracellular matrix, today ... company developing and commercializing products targeting the extracellular matrix for the drug delivery, ... of different enzymes in its portfolio that are targeting significant areas of unmet need. Safe Harbor ...

JCI online early table of contents: March 6, 2008

... of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells AUTHOR ... genes were generated. A similar approach rAAV targeting of the CFTR gene in ferret fibroblasts, followed ... pigs by adeno-associated virusmediated gene targeting and somatic cell nuclear transfer AUTHOR ...

Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity

... - Data Further Supports High Degree of Tumor targeting Specificity for Bavituximab, Currently in Phase ... Cancer Research that supports the specific tumor targeting properties of the company's novel ... bone and brain. The tumor blood vessel-selective targeting observed in vivo in the study was confirmed by ...

ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting

... are findings from our cancer stem cell programs targeting CD44 and CD9. This is an exciting new area of ... 3990: "AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple ... Abstract Number 3995: "A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement activity ...

deCODE genetics Announces Third Quarter 2007 Financial Results

... CEO of deCODE. "In our drug development program targeting the leukotriene pathway for the prevention of ... -- Heart attack. In its drug development program targeting the leukotriene pathway for the prevention of ... supports DG041's development as a compound targeting a key mechanism involved in the formation of ...

Arius announces new findings in Trop-2 and CD59 CANCER antibody programs

... Proffered Paper Presentation ARIUS' Trop-2 targeting antibody has demonstrated a ... a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human ... cancer cells from being destroyed. Our CD59 targeting antibody provides a novel approach to "de-cloak" ...

ARIUS announces cancer stem cell antibody program successfully completes first toxicology study

... -Lead antibody targeting novel epitope of CD44 found in breast colon, and ... cancers. Two humanized versions of the CD44 targeting antibody have been generated in preparation for ... ARH460-16-2, a therapeutic monoclonal antibody targeting CD44." Session B, Wednesday, October 24, 2007, ...

Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference

... a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human ... examine the mechanism of action of its Trop-2 targeting antibody. Trop-2 is a protein expressed on the ... A70: "AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits ...

Vasogen Announces Third Quarter 2007 Results

... was attended by physicians whom Ferrer is targeting to participate in the initial roll-out of ... heart failure patients. Ferrer is initially targeting Germany and Spain for the initial commercial ... These results provide a strong basis for targeting Celacade's novel anti-inflammatory mechanism ...

Arius Features Preclinical Data on Antibody Candidates at Two Conferences

... of a potent therapeutic monoclonal antibody targeting CD44 in breast cancer" and will be presented at ... demonstrating that its monoclonal antibody targeting CD59, a cell surface molecule involved in ... is entitled "AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits ...

Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway

... development of fully human monoclonal antibodies targeting the IGF pathway and system in the search for ... IGF-II and IGF-I. "Recently several antibodies targeting IGF-IR have entered clinical trials. Antibodies ... safe and effective for treatment of cancer by targeting the insulin growth factor pathway, determinations ...

Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents

... development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of ... and, unlike DNA mutations, may be reversed by targeting the enzymes involved. The silencing of key cell ... Gemzar(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration ... antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration ... antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of ...

Micromet Announces Pricing of Public Offering of Common Stock

... with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration ... antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of ...

Micromet Announces Public Offering of Common Stock

... with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration ... antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration ... antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of ...

Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited

... as many deaths as MRSA. Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include ... methicillin-resistant Staphylococcus aureus (MRSA) infection and others targeting Gram-negative infections. For further information, please visit our ...

Micromet Added to Russell 3000 Index

... with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration ... antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of ...

The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers

... unprecedented single-agent efficacy in many cancers. By selectively targeting cancers and their associated blood supply, while sparing normal cells and ... unsung hero. For further information about Rexin-G, high-performance targeting technologies, and/or new products in development, see ...

Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases

... our drug candidate CEQ508, an orally administered tk RNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous ... first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company ...